FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

Becton Dickinson and Check-Points Snag CE Mark for Resistant Bacteria Screening Assay

Jan. 19, 2018
A A

Becton Dickinson and Netherlands-based Check-points Health received a CE Mark for a molecular screening assay to detect carbapenemase-producing organisms.

The organisms have acquired the ability to produce carbapenemase, an enzyme that renders carbapenem antibiotics ineffective.

The BD MAX Check-Points assay can detect five common carbapenemase genes. It can be completed in less than 2.5 hours, which is up to 10 times faster than traditional tests, enabling earlier infection control measures.

View today's stories